MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.01
+3.13
+14.31%
After Hours: 25.01 0 0.00% 16:51 02/26 EST
OPEN
22.03
PREV CLOSE
21.88
HIGH
25.80
LOW
22.03
VOLUME
2.36M
TURNOVER
--
52 WEEK HIGH
32.18
52 WEEK LOW
4.040
MARKET CAP
1.41B
P/E (TTM)
-7.9835
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Morgan Stanley Keeps Their Sell Rating on MacroGenics (MGNX)
Morgan Stanley analyst David Lebovitz maintained a Sell rating on MacroGenics (MGNX) today and set a price target of $15.00. The company's shares closed
SmarterAnalyst · 2d ago
DJ Incyte: EMA Validates Application for Retifanlimab in Squamous Cell Anal Carcinoma
Dow Jones · 2d ago
DJ Macrogenics Is Maintained at Underweight by Morgan Stanley
Dow Jones · 2d ago
DJ Macrogenics Price Target Raised to $15.00/Share From $14.00 by Morgan Stanley
Dow Jones · 2d ago
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a...
GlobeNewswire · 2d ago
--Analyst Actions: Credit Suisse Raises MacroGenics' Price Target to $37 from $36 on First Commercial Launch, Continued Pipeline Progress; Maintains Outperform Rating
MT Newswires · 2d ago
--Analyst Actions: Wedbush Adjusts Price Target on MacroGenics to $39 From $37, Keeps Outperform Rating
MT Newswires · 3d ago
DJ MacroGenics, Inc. CEO Scott Koenig on Q4 2020 Results -- Earnings Call Transcript >MGNX
Dow Jones · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGNX. Analyze the recent business situations of MacroGenics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGNX stock price target is 31.10 with a high estimate of 39.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 230
Institutional Holdings: 64.02M
% Owned: 113.91%
Shares Outstanding: 56.20M
TypeInstitutionsShares
Increased
63
5.29M
New
35
645.65K
Decreased
35
6.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Paulo Costa
President/Chief Executive Officer/Director
Scott Koenig
Chief Financial Officer/Senior Vice President/Secretary
James Karrels
Senior Vice President/Chief Scientific Officer
Ezio Bonvini
Senior Vice President
Stephen Eck
Senior Vice President
Eric Risser
Senior Vice President
Thomas Spitznagel
Vice President/General Counsel
Jeffrey Peters
Vice President/Controller/Treasurer
Lynn Cilinski
Director
Federica O'Brien
Independent Director
Karen Ferrante
Independent Director
Kenneth Galbraith
Independent Director
Edward Hurwitz
Independent Director
Scott Jackson
Independent Director
Jay Siegel
Independent Director
David Stump
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About MGNX
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.